Melbourne, 18-19 July 2014
The recent development of highly effective antiviral therapy for HBV and HCV provides the opportunity to counter the rising burden of chronic liver disease among people living with HIV. Global antiretroviral therapy scale-up should limit HBV-related liver disease, through dual antiviral activity. Furthermore, development of antiretroviral therapy delivery infrastructure should enhance implementation of interferon-free direct acting antiviral (DAA) regimens for HCV once available. However, several barriers to access and impact of new HCV therapies exist including low levels of HCV screening, limited liver disease staging, and lack of HCV-specific education and training of HIV health care professionals. The focus of the meeting will be development of strategies to enhance implementation of viral hepatitis antiviral therapy, particularly in preparation for the highly effective interferon-free DAA regimens for chronic HCV.
The European AIDS Clinical Society is happy to collaborate to the
ASHM International HIV/Viral Hepatitis Coinfection Meeting, an affiliated independent event with the 20th International AIDS Conference, Melbourne, 18-19 July 2014